Does the media prefer NTRA or ARWR?

In the previous week, Natera had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 17 mentions for Natera and 16 mentions for Arrowhead Pharmaceuticals. Natera's average media sentiment score of 1.06 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RVMD or ARWR?

In the previous week, Revolution Medicines had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 17 mentions for Revolution Medicines and 16 mentions for Arrowhead Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.69 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or BIIB?

In the previous week, Biogen had 7 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 23 mentions for Biogen and 16 mentions for Arrowhead Pharmaceuticals. Biogen's average media sentiment score of 1.02 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or ARWR?

In the previous week, Alnylam Pharmaceuticals and Alnylam Pharmaceuticals both had 16 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 0.87 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARWR or INSM?

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Insmed. MarketBeat recorded 16 mentions for Arrowhead Pharmaceuticals and 10 mentions for Insmed. Insmed's average media sentiment score of 1.00 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arrowhead Pharmaceuticals (ARWR) Competitors

$85.11 -1.23 (-1.42%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$85.60 +0.48 (+0.57%)

As of 04:54 AM Eastern

Compare

ARWR vs. NTRA, RVMD, BIIB, ALNY, and INSM

Should you buy Arrowhead Pharmaceuticals stock or one of its competitors? Arrowhead Pharmaceuticals's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arrowhead Pharmaceuticals compare to Natera?

Natera (NASDAQ:NTRA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Natera had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 17 mentions for Natera and 16 mentions for Arrowhead Pharmaceuticals. Natera's average media sentiment score of 1.06 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera presently has a consensus target price of $322.50, indicating a potential downside of 0.51%. Arrowhead Pharmaceuticals has a consensus target price of $99.15, indicating a potential upside of 16.50%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.26	-$208.16M	-$1.36	N/A
Arrowhead Pharmaceuticals	$829.45M	14.45	-$1.63M	-$2.25	N/A

99.9% of Natera shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Natera has a net margin of -7.11% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Natera's return on equity of -11.38% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Natera has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Summary

Natera beats Arrowhead Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Arrowhead Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,837.39	-$1.13B	-$8.82	N/A
Arrowhead Pharmaceuticals	$829.45M	14.45	-$1.63M	-$2.25	N/A

In the previous week, Revolution Medicines had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 17 mentions for Revolution Medicines and 16 mentions for Arrowhead Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.69 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Revolution Medicines presently has a consensus price target of $200.74, indicating a potential downside of 3.18%. Arrowhead Pharmaceuticals has a consensus price target of $99.15, indicating a potential upside of 16.50%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Revolution Medicines has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Revolution Medicines has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Summary

Revolution Medicines beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Biogen?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Biogen had 7 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 23 mentions for Biogen and 16 mentions for Arrowhead Pharmaceuticals. Biogen's average media sentiment score of 1.02 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	15 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biogen has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.45	-$1.63M	-$2.25	N/A
Biogen	$9.89B	3.17	$1.29B	$5.65	37.61

Arrowhead Pharmaceuticals presently has a consensus price target of $99.15, suggesting a potential upside of 16.50%. Biogen has a consensus price target of $228.50, suggesting a potential upside of 7.53%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Biogen has a net margin of 8.32% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Biogen's return on equity of 11.18% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Biogen	8.32%	11.18%	6.88%

Summary

Biogen beats Arrowhead Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Alnylam Pharmaceuticals currently has a consensus target price of $382.96, indicating a potential upside of 47.23%. Arrowhead Pharmaceuticals has a consensus target price of $99.15, indicating a potential upside of 16.50%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Alnylam Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	9.37	$313.75M	$5.38	48.35
Arrowhead Pharmaceuticals	$829.45M	14.45	-$1.63M	-$2.25	N/A

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals and Alnylam Pharmaceuticals both had 16 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 0.87 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alnylam Pharmaceuticals beats Arrowhead Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Insmed?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Insmed. MarketBeat recorded 16 mentions for Arrowhead Pharmaceuticals and 10 mentions for Insmed. Insmed's average media sentiment score of 1.00 beat Arrowhead Pharmaceuticals' score of 0.59 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals currently has a consensus target price of $99.15, indicating a potential upside of 16.50%. Insmed has a consensus target price of $205.52, indicating a potential upside of 64.56%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Insmed's net margin of -76.94%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Insmed	-76.94%	-123.94%	-44.30%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than Insmed. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.45	-$1.63M	-$2.25	N/A
Insmed	$606.42M	44.97	-$1.28B	-$4.11	N/A

Summary

Arrowhead Pharmaceuticals beats Insmed on 10 of the 17 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARWR vs. The Competition

Export

Metric	Arrowhead Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.16B	$4.01B	$7.39B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.14%
P/E Ratio	-37.83	12.50	270.75	25.39
Price / Sales	14.45	1,469.43	656.33	96.79
Price / Cash	723.11	108.60	77.07	52.39
Price / Book	23.38	15.96	10.88	6.40
Net Income	-$1.63M	-$22.81M	$3.48B	$358.18M
7 Day Performance	-0.30%	-0.87%	-0.98%	0.04%
1 Month Performance	-2.90%	4.83%	2.91%	-0.80%
1 Year Performance	206.92%	47.27%	22.21%	12.47%

Arrowhead Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARWR Arrowhead Pharmaceuticals	2.2792 of 5 stars	$85.11 -1.4%	$99.15 +16.5%	+213.2%	$12.16B	$829.45M	N/A	400	Analyst Forecast Gap Down
NTRA Natera	2.4319 of 5 stars	$321.96 -1.3%	$319.38 -0.8%	+93.6%	$47.03B	$2.31B	N/A	6,140	Positive News Analyst Upgrade
RVMD Revolution Medicines	2.4708 of 5 stars	$205.57 -1.1%	$200.74 -2.4%	+404.9%	$44.56B	$11.58M	N/A	250
BIIB Biogen	3.7239 of 5 stars	$216.65 -0.8%	$227.79 +5.1%	+50.3%	$32.28B	$9.89B	38.35	7,500	Positive News Gap Down
ALNY Alnylam Pharmaceuticals	4.6013 of 5 stars	$240.69 +1.5%	$386.14 +60.4%	-42.8%	$31.73B	$3.71B	44.74	2,770	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARWR) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does Arrowhead Pharmaceuticals compare to Natera?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to Biogen?

Summary

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Arrowhead Pharmaceuticals compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does Arrowhead Pharmaceuticals compare to Natera?

Does the media prefer NTRA or ARWR?

Do analysts prefer NTRA or ARWR?

Which has better earnings & valuation, NTRA or ARWR?

Do institutionals and insiders hold more shares of NTRA or ARWR?

Is NTRA or ARWR more profitable?

Which has more risk & volatility, NTRA or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Which has better earnings and valuation, RVMD or ARWR?

Does the media refer more to RVMD or ARWR?

Do insiders & institutionals believe in RVMD or ARWR?

Do analysts recommend RVMD or ARWR?

Is RVMD or ARWR more profitable?

Which has more risk & volatility, RVMD or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Biogen?

Does the media favor ARWR or BIIB?

Which has more volatility & risk, ARWR or BIIB?

Do institutionals & insiders have more ownership in ARWR or BIIB?

Which has stronger earnings and valuation, ARWR or BIIB?

Do analysts rate ARWR or BIIB?

Is ARWR or BIIB more profitable?

Summary

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Do analysts prefer ALNY or ARWR?

Which has more risk & volatility, ALNY or ARWR?

Is ALNY or ARWR more profitable?

Which has preferable valuation & earnings, ALNY or ARWR?

Do institutionals and insiders hold more shares of ALNY or ARWR?

Does the media favor ALNY or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Insmed?

Which has more risk and volatility, ARWR or INSM?

Does the media prefer ARWR or INSM?

Do analysts rate ARWR or INSM?

Is ARWR or INSM more profitable?

Do insiders & institutionals believe in ARWR or INSM?

Which has better valuation and earnings, ARWR or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools